Pcas SA
PAR:PCA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8
8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pcas SA
Pcas SA
Net Issuance of Debt
Pcas SA
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pcas SA
PAR:PCA
|
Net Issuance of Debt
-€4.2m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Net Issuance of Debt
€1.3B
|
CAGR 3-Years
109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pcas SA
Glance View
PCAS SA engages in the development, manufacture, and sale of chemicals. The company is headquartered in Ecully, Auvergne-Rhone-Alpes. The company operates through nine production sites and two main business units, Pharma Synthesis and Fine & Specialty Chemicals. Pharma Synthesis unit specializes in active pharmaceutical ingredients (API), intermediates and building blocks, and early phase services, among others. Fine & Specialty Chemicals unit focuses on custom manufacturing and proprietary products, such as fragrance, flavor ingredients, imaging and microelectronics chemicals. The firm operates several subsidiaries, including Saint-Jean Photochimie, Societe Bearnaise de Synthese, Expansia, PCAS BioMatrix Inc, based in Canada, and PCAS Finland Oy, based in Finland, among others.
See Also
What is Pcas SA's Net Issuance of Debt?
Net Issuance of Debt
-4.2m
EUR
Based on the financial report for Jun 30, 2023, Pcas SA's Net Issuance of Debt amounts to -4.2m EUR.
What is Pcas SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-10%
The average annual Net Issuance of Debt growth rates for Pcas SA have been -58% over the past three years , and -10% over the past ten years .
You don't have any saved screeners yet
